In the last trading session, 1.57 million shares of the Biohaven Ltd (NYSE:BHVN) were traded, and its beta was 4.27. Most recently the company’s share price was $18.51, and it changed around $0.89 or 5.05% from the last close, which brings the market valuation of the company to $1.89B. BHVN currently trades at a discount to its 52-week high of $55.70, offering almost -200.92% off that amount. The share price’s 52-week low was $15.79, which indicates that the current value has risen by an impressive 14.69% since then. We note from Biohaven Ltd’s average daily trading volume that its 10-day average is 1.99 million shares, with the 3-month average coming to 1.16 million.
Biohaven Ltd stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 0 recommended BHVN as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Biohaven Ltd is expected to report earnings per share of -1.49 for the current quarter.
Biohaven Ltd (NYSE:BHVN) trade information
Instantly BHVN has showed a green trend with a performance of 5.05% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 19.30 on recent trading dayincreased the stock’s daily price by 4.09%. The company’s shares are currently down -50.44% year-to-date, but still up 3.35% over the last five days. On the other hand, Biohaven Ltd (NYSE:BHVN) is -36.50% down in the 30-day period. We can see from the shorts that 7.49 million shares have been sold at a short interest cover period of 5.94 day(s).
The consensus price target as assigned by Wall Street analysts is $60.5, which translates to bulls needing to increase their stock price by 69.4% from its current value. Analyst projections state that BHVN is forecast to be at a low of $57 and a high of $65.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 1.25M in revenue for the current quarter. 10 analysts expect Biohaven Ltd to make 1.25M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -49.78%. Biohaven Ltd earnings are expected to increase by 26.30% in 2025, but the outlook is positive 22.09% per year for the next five years.
BHVN Dividends
Biohaven Ltd’s next quarterly earnings report is expected to be released on 2025-Mar-02.
Biohaven Ltd (NYSE:BHVN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.97% of Biohaven Ltd shares, and 91.83% of them are in the hands of institutional investors. The stock currently has a share float of 104.32%. Biohaven Ltd stock is held by 346.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 8.9114% of the shares, which is about 7.27 million shares worth $252.41 million.
STIFEL FINANCIAL CORP, with 7.3839% or 6.48 million shares worth $224.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.51 shares worth $46.47 million, making up 2.46% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 2.21 shares worth around $40.96 million, which represents about 2.17% of the total shares outstanding.
